source
- Argenx’s FB102 meets primary endpoint in phase 2 celiac trial, paving way for pivotal studyArgenx reported that its experimental antibody FB102 achieved a statistically significant improvement in villus height‑to‑crypt depth (Vh:Cd) compared with placebo in a phase 2 study of adults with…
- Congressional Bill Aims to End Arbitration in No Surprises Act, Shifting Payments to Median In-Network RatesRep. Frank Pallone introduced the Lower Premiums, Faster Payments Act, which would eliminate the arbitration system used under the No Surprises Act and replace it with a payment model based on medi…